Get Premium to unlock powerful stock data
Orgenesis Inc logo

Orgenesis Inc

$ 2.39 +0.04 (+1.7%) 09:08 PM EST
P/E:
At Loss
P/B:
1.49
Market Cap:
$ 59.32M
Enterprise V:
$ 64.70M
Volume:
41.60K
Avg Vol (2M):
56.71K
Also Trade In:
Volume:
41.60K
Market Cap $:
59.32M
PE Ratio:
At Loss
Avg Vol (2-Month):
56.71K
Enterprise Value $:
64.70M
PB Ratio:
1.49
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Orgenesis Inc () from 2010 to May 26 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Orgenesis stock (ORGS) PE ratio as of May 26 2022 is 0. More Details

Orgenesis PE Ratio (TTM) Chart

EMBED

Orgenesis PE Ratio (TTM) Historical Data

Total 1268
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Orgenesis PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-05-26At Loss 2022-03-24At Loss
2022-05-25At Loss 2022-03-23At Loss
2022-05-24At Loss 2022-03-22At Loss
2022-05-23At Loss 2022-03-21At Loss
2022-05-20At Loss 2022-03-18At Loss
2022-05-19At Loss 2022-03-17At Loss
2022-05-18At Loss 2022-03-16At Loss
2022-05-17At Loss 2022-03-15At Loss
2022-05-16At Loss 2022-03-14At Loss
2022-05-13At Loss 2022-03-11At Loss
2022-05-12At Loss 2022-03-10At Loss
2022-05-11At Loss 2022-03-09At Loss
2022-05-10At Loss 2022-03-08At Loss
2022-05-09At Loss 2022-03-07At Loss
2022-05-06At Loss 2022-03-04At Loss
2022-05-05At Loss 2022-03-03At Loss
2022-05-04At Loss 2022-03-02At Loss
2022-05-03At Loss 2022-03-01At Loss
2022-05-02At Loss 2022-02-28At Loss
2022-04-29At Loss 2022-02-25At Loss
2022-04-28At Loss 2022-02-24At Loss
2022-04-27At Loss 2022-02-23At Loss
2022-04-26At Loss 2022-02-22At Loss
2022-04-25At Loss 2022-02-21At Loss
2022-04-22At Loss 2022-02-18At Loss
2022-04-21At Loss 2022-02-17At Loss
2022-04-20At Loss 2022-02-16At Loss
2022-04-19At Loss 2022-02-15At Loss
2022-04-18At Loss 2022-02-14At Loss
2022-04-15At Loss 2022-02-11At Loss
2022-04-14At Loss 2022-02-10At Loss
2022-04-13At Loss 2022-02-09At Loss
2022-04-12At Loss 2022-02-08At Loss
2022-04-11At Loss 2022-02-07At Loss
2022-04-08At Loss 2022-02-04At Loss
2022-04-07At Loss 2022-02-03At Loss
2022-04-06At Loss 2022-02-02At Loss
2022-04-05At Loss 2022-02-01At Loss
2022-04-04At Loss 2022-01-31At Loss
2022-04-01At Loss 2022-01-28At Loss
2022-03-31At Loss 2022-01-27At Loss
2022-03-30At Loss 2022-01-26At Loss
2022-03-29At Loss 2022-01-25At Loss
2022-03-28At Loss 2022-01-24At Loss
2022-03-25At Loss 2022-01-21At Loss

Orgenesis PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Orgenesis Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325412 SIC : 2834
Traded in other countries / regions
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.